Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial
详细信息 查看全文
- 作者：Birgit Steppich ; Philip Groha ; Tareq Ibrahim…
- 关键词：Erythropoietin ; Acute myocardial infarction ; REVIVAL ; 3 trial
- 刊名：BMC Cardiovascular Disorders
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：17
- 期：1
- 全文大小：646KB
- 刊物主题：Cardiology; Cardiac Surgery; Angiology; Blood Transfusion Medicine; Internal Medicine; Medicine/Public Health, general;
- 出版者：BioMed Central
- ISSN：1471-2261
- 卷排序：17
文摘
BackgroundErythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely reperfused myocardium does not improve left ventricular ejection fraction after 6 months. Moreover, the study raised safety concerns due to a trend towards a higher incidence of adverse clinical events as well as a increase in neointima formation after treatment with EPO. The present study therefore aimed to assess the 5-year clinical outcomes.